ProgniaPrognia
Back to Guidelines
Center for Biologics Evaluation and Research, U.S. Food and Drug Administrationnational1992

Regulatory considerations when developing biological products. Report of the Center for Biologics Evaluation and Research.

Published by Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

Summary

AI-generated

The Center for Biologics Evaluation and Research, whose regulatory authority includes monoclonal antibodies, cytokines, vaccines, toxins and somatic cellular therapies, communicates to sponsors issues for consideration in the development of biological products through the publication of "Points to Consider" and "Guideline" documents. This paper summarizes the available "Points to Consider" and "Guideline" documents and outlines recommendations from these documents for characterizing the cells used to produce biological products.

Patient Criteria & Setting

Therapeutic Area

national